Letzte Aktualisierung: 05.04.2023

Urothelkarzinom der Blase

MoniTURB Trial

Aktive Studien

Studieninformationen

Xpert Bladder Cancer Monitor

to Predict Need for 2nd TURB

Behandlungszentren im CIO

Bonn


Ziele

Primäres Prüfziel

The primary objective of this prospective, multi-centre study is to determine if Xpert Monitor can predict the need for a second TURB better than the clinical risk assessment by predicting the presence of a residual tumor after a patient has undergone an initial resection to remove tumour (first TURB).

Sekundäre Prüfziele für die Behandlungsarme:

In a secondary objective, Xpert Monitor performance shall be established relative to cystoscopy in patients with non-muscle invasive bladder cancer (NMIBC) who, based on their clinical risk assessment, were not selected for second TURB but received a monitor cystoscopy 3-6 months after the first TURB.


Design

Phase

Zentren

Datenerhebung

Interventionsgruppen

Verblindung

Erkrankung

Diagnose

Urothelkarzinom der Blase

Diagnosenbeschreibung

Mutation

Stadium

Patienten

Alter

Einschlusskriterien

Ausschlusskriterien

Therapie

Intervention

Substanz

Sonstiges

Zuständige Gesamtstudie

Sponsor

Leiter der klinischen Prüfung (LKP)

Studiengruppen/-zentrale

Kontakt Klinische Studien

CIO Aachen: Uniklinik RWTH Aachen, +49 (0) 241 80-85490

CIO Bonn: Uniklinik Bonn, +49 (0) 228 287-16036

CIO Köln: Uniklinik Köln, +49 (0) 221 478-0

CIO Düsseldorf: Uniklinik Düsseldorf, +49 (0) 211 81-04150 (Mo-Do)